Financials in USD. Standardized financial statements.
A compact view of how Ambrx Biopharma Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $7.40M | $7.46M | $13.67M | $10.31M |
| Revenue Growth? | -0.7% | -45.5% | +32.6% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $7.40M | $7.46M | $13.67M | $10.31M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $74.14M | $71.88M | $26.79M | $32.78M |
| Operating Income? | -$57.08M | -$64.42M | -$13.12M | -$22.47M |
| EBITDA? | -$63.17M | -$62.27M | -$11.17M | -$20.42M |
| Income Before Tax | -$76.06M | -$68.29M | -$17.84M | -$22.32M |
| Income Tax Expense | $1.94M | $1,000 | $1,000 | -$2,000 |
| Net Income? | -$78.00M | -$68.29M | -$17.84M | -$22.31M |
| EPS? | $-2.02 | $-3.34 | $-0.47 | $-0.59 |
| Diluted EPS? | $-2.02 | $-3.34 | $-0.47 | $-0.59 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality